scholarly journals Hand and Foot Syndrome Associated with Capecitabine

2020 ◽  
pp. 1-6
Author(s):  
Louai Alsaloumi ◽  
Louai Alsaloumi ◽  
Shaima Shawagfeh ◽  
Bilgen Başgut

Having cancer impacts the patient both psychologically and physically. However, if cancer is accompanied with HFS, the patient’s condition gets even worse. Capecitabine is a prodrug approved to treat several types of cancer such as breast and colorectal cancer. It is associated with several adverse effects such as hand and foot syndrome (HFS) which mostly affects the palms and legs. The provoked mechanisms of HFS are not clear yet. They require further validation of HFS pathogenesis. Up to now, prevention and treatment of HFS are not clearly solidified. Evidence supports the use of celecoxib, urea-based creams, and vitamin E to reduce the severity and the incidence of HFS. This review aims to provide the gaps and ways to further clinical evaluations.

2018 ◽  
Vol 35 (2) ◽  
pp. 413-421
Author(s):  
G.A Shams ◽  
M.A. Kamel ◽  
R.M. Ezzat
Keyword(s):  

2015 ◽  
Vol 87 (9) ◽  
Author(s):  
Łukasz Dziki ◽  
Anna Puła ◽  
Konrad Stawiski ◽  
Barbara Mudza ◽  
Marcin Włodarczyk ◽  
...  

Abstractwas to assess patients’ awareness of the prevention and treatment of colorectal cancer.Patients diagnosed with colorectal cancer, hospitalised at the Department of General and Colorectal Surgery of the Medical University in Łódź during the period from January 2015 to April 2015, were asked to complete a questionnaire concerning their families’ medical case record, factors predisposing them to the development of colorectal cancer, the tests applied in diagnostics, and the treatment process. The questionnaire comprised 42 closed-ended questions with one correct answer. A statistical analysis of all answers was carried out.The study group consisted of 30 men and 20 women aged 27–94 years old. A strong, statistically significant negative correlation between a patient’s age and his/her awareness of the prevention and treatment of colorectal cancer was noted (p<0.001; r= −0.51). The study demonstrated a statistically significant relationship between the occurrence of neoplasms in a patient’s family (p=0.009) or, more specifically, the occurrence of colorectal cancer (p=0.008), and the awareness of the prevention programme. The women’s group was characterised by statistically significantly greater awareness of colonoscopy as a screening examination (p=0.004).Patients need more information on colorectal cancer, its risk factors, prevention, the treatment process, and postoperative care. Lack of awareness of the colorectal cancer issue can be one of the major factors contributing to the high incidence of this disease.


2021 ◽  
pp. 247255522110024
Author(s):  
Yunhong Nong ◽  
Yanyan Hou ◽  
Yuting Pu ◽  
Si Li ◽  
Yan Lan

Throughout recent decades, histone deacetylase (HDAC) inhibitors have shown encouraging potential in cancer treatment, and several pan-HDAC inhibitors have been approved for treating malignant cancers. Numerous adverse effects of pan-HDAC inhibitors have been reported, however, during preclinical and clinical evaluations. To avoid undesirable responses, an increasing number of investigations are focusing on the development of isotype-selective HDAC inhibitors. In this study, we present an effective and quantitative cellular assay using high-content analysis (HCA) to determine compounds’ inhibition of the activity of HDAC6 and Class I HDAC isoforms, by detecting the acetylation of their corresponding substrates (i.e., α-tubulin and histone H3). Several conditions that are critical for HCA assays, such as cell seeding number, fixation and permeabilization reagent, and antibody dilution, have been fully validated in this study. We used selective HDAC6 inhibitors and inhibitors targeting different HDAC isoforms to optimize and validate the capability of the HCA assay. The results indicated that the HCA assay is a robust assay for quantifying compounds’ selectivity of HDAC6 and Class I HDAC isoforms in cells. Moreover, we screened a panel of compounds for HDAC6 selectivity using this HCA assay, which provided valuable information for the structure–activity relationship (SAR). In summary, our results suggest that the HCA assay is a powerful tool for screening selective HDAC6 inhibitors.


RSC Advances ◽  
2015 ◽  
Vol 5 (66) ◽  
pp. 53846-53856 ◽  
Author(s):  
Shihou Sheng ◽  
Tao Zhang ◽  
Shijie Li ◽  
Jun Wei ◽  
Guangjun Xu ◽  
...  

A traditional Chinese medicine cantharidin which was previously found to be effective on colorectal cancer cells was translated into nanoparticles for drug delivery to reduce its side effects and enhance its drug efficacy.


2017 ◽  
Vol 22 (3) ◽  
pp. 164-168
Author(s):  
Andrey A. Meshcheryakov

The review analyzed data from the literature and personal experience of the application of anti-angiogenic therapy in metastatic colorectal cancer. There are presented practical advices on prevention and treatment of the most common side effects of anti-angiogenic therapy.


2008 ◽  
Vol 204 (7) ◽  
pp. 469-477 ◽  
Author(s):  
Neel Sengupta ◽  
Kathryn A. Gill ◽  
Tammie S. MacFie ◽  
Cecilia S. Lai ◽  
Nirosha Suraweera ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document